title: Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.
abstract: Topotecan is indicated in the treatment of advanced-stage ovarian cancers refractory to prior platinum-based regimen. The aim of this study was to compare the standard therapeutic strategy with a novel strategy of weekly administration of topotecan. The primary endpoints were dose density and overall tolerance. This retrospective cohort study included patients with ovarian cancer in relapse. During a first period (1998-2001), 24 patients received the standard topotecan dose of 1.5 mg/m(2)/day for 5 consecutive days with a 3-week interval between each treatment course. During a second period (2003-2006), 21 patients received a weekly topotecan dose of 4 mg/m(2) for 3 weeks out of every 4. Grades III and IV haematological toxicities were more frequent with the standard strategy (p < 0.05), even after adjustment of the prescription of erythropoietin and G-CSF. With the weekly strategy, an increase in dose density and a reduction in the number of delayed doses were observed. No significant difference between the 2 strategies was found in terms of response to the treatment and specific survival. This study suggests that the weekly administration of topotecan 4 mg/m(2), for 3 weeks out of every 4, results in a better maintenance of dose density and a reduction in haematological toxicity.
authors.affiliation: Centre Antoine Lacassagne, Nice, France.
authors.forename: R
authors.initials: R
authors.lastname: Largillier
authors.forename: B
authors.initials: B
authors.lastname: Valenza
authors.forename: J-M
authors.initials: JM
authors.lastname: Ferrero
authors.forename: C
authors.initials: C
authors.lastname: Novo
authors.forename: A
authors.initials: A
authors.lastname: Creisson
authors.forename: G
authors.initials: G
authors.lastname: Lesbats
authors.forename: V
authors.initials: V
authors.lastname: Mari
authors.forename: C
authors.initials: C
authors.lastname: Hebert
authors.forename: E
authors.initials: E
authors.lastname: Chamorey
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy / Q000556:secondary; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy / Q000556:secondary; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015331:Cohort Studies; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy / Q000556:secondary; D004305:Dose-Response Relationship, Drug; D019008:Drug Resistance, Neoplasm; D016889:Endometrial Neoplasms / Q000188:drug therapy / Q000556:secondary; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012189:Retrospective Studies; D015996:Survival Rate; D019772:Topotecan / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D019772:Topotecan